mp.weixin.qq.com· 良医汇肿瘤资讯·· 4 hours agoPickScore79
2026 ESMO Preview: Pimicotinib MANEUVER 2-Year TGCT Follow-Up and Three Nirogacestat Desmoid Tumor Datasets
2026 ESMO前瞻丨聚焦TGCT与硬纤维瘤：匹米替尼MANEUVER研究2年随访数据公布，尼罗司他真实世界与剂量策略证据亮相
In brief
Five studies from Merck KGaA's pimicotinib and nirogacestat were accepted for the 2026 ESMO congress, covering long-term follow-up and quality of life in TGCT, as well as dose-reduction, real-world, and indirect comparison evidence in desmoid tumors.
Why it matters
Presents pimicotinib long-term follow-up and quality of life results alongside nirogacestat dose-reduction, real-world, and indirect comparison evidence for comparing efficacy and safety.
Source: mp.weixin.qq.com · mp.weixin.qq.com